<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285844</url>
  </required_header>
  <id_info>
    <org_study_id>RDK071309</org_study_id>
    <nct_id>NCT00285844</nct_id>
  </id_info>
  <brief_title>Integrating the Genetic and Metabolic Faces of Obesity</brief_title>
  <official_title>Integrating the Genetic and Metabolic Faces of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine why some obese individuals develop insulin resistance
      and others do not. We hypothesize that an impairment in differentiation of fat cells
      (adipocytes) is responsible for the development of insulin resistance in select obese
      individuals. This study will evaluate obese individuals at baseline with respect to
      characteristics of adipocytes, including gene expression, and will then entail randomizing
      subjects to either weight loss or treatment with an insulin sensitizing drug (pioglitazone).
      Changes in insulin resistance will be associated with changes in adipocyte morphology and
      gene expression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy overweight/obese individuals will be screened for insulin resistance. Both insulin
      resistant individuals and insulin sensitive individuals (to serve as controls) will be
      eligible to enroll. Fat cel biopsy and CT scan of the abdomen is required at baseline and
      after an intervention with either weight loss or pioglitazone (drug to improve insulin
      resistance). Subjects will repeat insulin resistance test after the intervention as well.
      Subjects will learn much about their metabolism in this study, and will have an opportunity
      to improve their insulin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adipose Cell Size Distribution</measure>
    <time_frame>2005-2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adipose Tissue Gene Expression</measure>
    <time_frame>2005-2013</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Insulin-Mediated Glucose Uptake</measure>
    <time_frame>2005-2012</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IR and IS subjects will be randomized to pioglitazone 45 mg daily for 16 wks for comparison with dietary weight loss intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary Weight Loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IR and IS subjects will be randomized to dietary weight loss for 16 wks for comparison to pioglitazone intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>weight loss</intervention_name>
    <arm_group_label>Dietary Weight Loss</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiazolidinedione</intervention_name>
    <arm_group_label>pioglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nondiabetic defined as fasting plasma glucose &lt; 126 mg/dL

          -  body mass index 27 to 35 kg/m2

          -  no major organ diseases

          -  able to come to Stanford for regular clinical research center visits

          -  English speaking or has own translator

        Exclusion Criteria:

          -  pregnancy/lactation

          -  history of eating disorder or major psychiatric illness

          -  allergy to thiazolidenedione

          -  elevation of liver enzymes (&gt; 2.5 times upper normal limit)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracey McLaughlin, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2006</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Tracey McLaughlin</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>thiazolidinedione</keyword>
  <keyword>weight loss</keyword>
  <keyword>adipose tissue</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>diabetes prevention</keyword>
  <keyword>cardiovascular disease prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>2,4-thiazolidinedione</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

